TNF increases camptothecin-induced apoptosis by inhibition of NF-κB

European Journal of Cancer

Volumn 39, Issue 10, 2003, Pages 1468-1477

  Valente, P ^a   Arzani, D ^b,d   Cesario, A ^c   Margaritora, S ^c   Carbone, E ^b   Russo, P ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

Author keywords

Apoptosis; Camptothecin; Cytotoxicity; DNA elongation; DNA synthesis cell cycle; NF B; Ovarian cancer cells; TNF

Indexed keywords

CAMPTOTHECIN; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; BINDING ASSAY; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; FILTER; FLOW CYTOMETRY; HUMAN; HUMAN CELL; METAPHASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; STAINING; TIME;

EID: 0037784224     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00301-0     Document Type: Article

References (27)

1. Barkett M., Gilmore T.D. Control of apoptosis by Rel/NF-kB transcription factor. Oncogene. 18:1999;6910-6924.
2. Mayo M.W., Baldwin A.S. The transcription factor NF-kappaB. control of oncogenesis and cancer therapy resistance Biochim. Biophys. Acta. 270:2000;M55-M62.
3. Huang T.T., Wuerzberger-Davis S.M., Seufzer J.et al. NF-kB activation by Camptothecin. J. Biochem. Chem. 275:2000;9501-9509.
4. Rath P.C., Aggarwal B.B. TNF-induced signaling in apoptosis. J. Clin. Immunol. 19:1999;350-364.
5. Schmitt C.A., Lowe S.W. Apoptosis and therapy. J. Pathol. 187:1999;127-137.
6. Wang C.-Y., Cusack J.C., Liu R., Baldwin A.S. Control of inducible chemoresistance. enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB Nature Med. 5:1999;412-417.
7. Vikhanskaya F., Falugi C., Valente P., Russo P. Human papillomavirus type 16 E6-enhanced susceptibility to apoptosis induced by TNF in A2780 human ovarian cancer cell line. Int. J. Cancer. 97:2002;732-739.
8. Pourquier P., Pommier Y. TopoisomeraseI-mediated DNA damage. Adv. Cancer Res. 80:2001;189-216.
9. Orengo G., Noviello E., Cimoli G.et al. Potentiation of Topoisomerase I and II inhibitors cell killing by Tumor Necrosis Factor. relationship to DNA strand breakage formation Jpn J. Cancer Res. 83:1992;1132-1136.
10. Valenti M., Cimoli G., Parodi S.et al. Potentiation of Tumor Necrosis Factor-mediated cell killing by VP16 on human ovarian cancer cell lines ["in vitro" results and clinical implications]. Eur. J. Cancer. 29A:1993;1157-1161.
11. Chou T.-C., Talalay P. Generalized equations for the analysis of inhibitors of Michaelis-Menten and higher order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur. J. Biochem. 115:1981;207-216.
12. Chou T.-C., Talalay P. A simple generalized equation for the analysis of multipleinhibitions of Michaelis-Menten kinetic systems. J. Biol. Chem. 252:1987;6438-6442.
13. Debernardis D., Stanzione S., Ottoboni C.et al. Endogenous TNF enhances Topoisomerase II inhibitors activity in human ovarian cancer cell lines. J. Pharmacol. Exper. Ther. 279:1996;84-90.
14. Covey J.M., D'Incalci M., Tilchen E.J., Zaharko D.S., Kohn K.W. Differences in DNA damage produced by incorporation of 5-Aza-2′-deoxycitidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cells. Cancer Res. 46:1986;5511-5517.
15. Russo P., Poggi L., Parodi S., Pedrini A.M., Kohn K.W., Pommier Y. Production of protein-associated DNA breaks by 8-methoxycaffeine, caffeine and 8-chlorocaffeine in isolated nuclei from L1210 cells. comparison with those produced by Topoisomerase II inhibitors Carcinogenesis. 12:1991;1781-1790.
16. Bertrand R., Pommier Y. Assessment of DNA damage in mammalian cells by filter elution methodology in cell growth and apoptosis. a pratical approach Studzinski G.P. DNA Damage. 1996;97-117 University Press, Oxford.
17. Shreiber E., Matthias P., Muller M.M., Schaffner W. Rapid detection of octamer binding proteins with "mini-extracts", prepared from a small number of cell. Nuc. Acids Res. 15:1989;6419-6421.
18. Utsugi T., Mattern M.R., Mirabelli C.K., Hanna N. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor. enhancement of topoisomerase activity as a mechanism of potentiaton Cancer Res. 50:1990;2636-2640.
19. Strumberg D., Pilon A.A., Smith M., Hickey R., Malkas L., Pommier Y. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5′-phosphorylated DNA double-strand breaks by replication runoff. Mol. Cell Biol. 20:2000;3977-3987.
20. Piret B., Piette J. Topoisomerase poisons activate the transcription factor NF-kappaB in ACH-2 and CEM cells. Nuc. Acid Res. 24:1996;4242-4248.
21. Wang C.-Y., Mayo M.W., Komeluk R.G., Goeddel D.V., Baldwin A.S. NF-κB antiapoptosis. induction of TRAF-1, TRAF-2, c-IAP1 and c-IAP-2 to suppress caspase-8 activation Science. 281:1998;1680-1683.
22. Elliott P.J., Adams J. Recent advances in understanding proteasome function. Curr. Opin. Drug Discovery Dev. 2:1999;484-490.
23. Cusack Jr. Jc, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systematic nuclear factor-kappaB Inhibition 1. Cancer Res 2000, 61, 3535-3540.
24. Champoux J.J. DNA topoisomerases. structure, function, and mechanism Ann. Rev. Biochem. 70:2001;369-413.
25. Garcia-Carbonero R., Supko J.G. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin. Cancer Res. 8:2002;641-661.
26. Hirte H.W., Miller D., Tonkin K.et al. A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma. Gynecol. Oncol. 64:1997;80-87.
27. Del Mastro L., Venturini M., Giannessi P.G.et al. Intraperitoneal infusion of recombinant human tumor necrosis factor and mitoxantrone in neoplastic ascites. a feasibility study Anticancer Res. 15:1995;2207-2212.